您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Celastramycin A
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Celastramycin A
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Celastramycin A图片
CAS NO:491600-94-3
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
Cas No.491600-94-3
化学名(3-chloro-5-hexyl-2,6-dihydroxyphenyl)(4,5-dichloro-1H-pyrrol-3-yl)-methanone
Canonical SMILESClC1=CC(CCCCCC)=C(O)C(C(C2=CC(Cl)=C(Cl)N2)=O)=C1O
分子式C17H18Cl3NO3
分子量390.7
溶解度≤20mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Celastramycin A is an antibiotic that inhibits the growth of bacteria and mycobacteria and is also a potent innate immune suppressor [1][2].

Celastramycin A is a benzoyl pyrrole-type compound isolated from endophytic bacteria Streptomyces MaB-QuH-8 living in plants of the Celastraceae family. Celastramycin A exhibited high activity against a series of multiresistent bacteria and mycobacteria [1]. Celastramycin A inhibited the growth of Gram-positive bacteria and mycobacteria with minimal inhibitory concentration (MIC) as low as 0.05 μg/ml [1]. In the ex vivo Drosophila culture system, Celastramycin A showed a potent immunosuppressive effect with IC50 value of 0.008 μg/mL. In human umbilical vein endothelial cells (HUVECs), Celastramycin A potently inhibited the production of IL-8 with IC50 value of 0.06 μg/mL. So Celastramycin A could be used as a lead compound for novel immunosuppressive agents [2].

References:
[1].  Pullen C, Schmitz P, Meurer K, et al. New and bioactive compounds from Streptomyces strains residing in the wood of Celastraceae. Planta. 2002 Nov;216(1):162-7.
[2].  Kikuchi H, Sekiya M, Katou Y, et al. Revised structure and synthesis of celastramycin a, a potent innate immune suppressor. Org Lett. 2009 Apr 16;11(8):1693-5.